Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Public ClinicalTrials.gov record NCT04797767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms
Study identification
- NCT ID
- NCT04797767
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 62 participants
Conditions and interventions
Conditions
- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia
- Mixed Phenotype Acute Leukemia
- Myeloid Neoplasm
- Recurrent Myeloid Sarcoma
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Mixed Phenotype Acute Leukemia
- Refractory Myeloid Neoplasm
- Relapsed Acute Biphenotypic Leukemia
- Relapsed Acute Myeloid Leukemia
- Relapsed Mixed Phenotype Acute Leukemia
- Relapsed Myeloid Neoplasm
Interventions
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Cladribine Drug
- Cytarabine Drug
- Mitoxantrone Drug
- Recombinant Granulocyte Colony-Stimulating Factor Biological
- Venetoclax Drug
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2022
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2028
- Last update posted
- Apr 16, 2026
2022 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04797767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04797767 live on ClinicalTrials.gov.